Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was partly driven by its softer quarterly ...
Guardant Health (NASDAQ:GH) executives highlighted new commercial initiatives for its Shield colorectal cancer screening test, continued growth drivers for its Guardant360 therapy selection franchise, ...
This release focuses on reinforcing reliability and usability within existing processes, helping teams operate with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results